Clinical trial · Interventional
Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
Phase 1-2a Dose-Ranging Study of the Triplet Combination of Carboplatin, Paclitaxel and TLK286 as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
NCT00088556CI-TRIAL-00007026completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this trial is to study the efficacy and safety of the triplet combination of TLK286, carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| carboplatin | Drug | Carboplatin | ALIAS |
| paclitaxel | Drug | Paclitaxel | ALIAS |
| TLK286 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Triplet Combination of TLK286 Carboplatin & Paclitaxel
- description
- Experimental
- interventionNames
- Drug: TLK286
- Drug: carboplatin
- Drug: paclitaxel
Primary outcomes (1)
- measure
- Study Objectives
- timeFrame
- Every 6 Weeks
- description
- 1. To determine the MTD of patients treated with the triplet combination of TLK286, paclitaxel and carboplatin 2. To determine the safety of patients treated with the triplet combination of TLK286, paclitaxel and carboplatin 3. To determine the objective response rate (ORR) of patients treated with the triplet combination of TLK286, paclitaxel and carboplatin
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years of age or older * Histologically confirmed non-small cell lung cancer (NSCLC) * Stage IV or IIIB (disease that is not eligible for combined modality chemotherapy and radiation) * Measurable disease by RECIST * ECOG status of 0-1 * Adequate liver and renal function * Adequate bone marrow reserves Exclusion Criteria: * Prior chemotherapy, immunotherapy or biologic therapy for metastatic NSCLC * Up to one prior adjuvant or neoadjuvant chemotherapy is allowed * History of bone marrow transplantation or stem cell support * Pregnant or lactating women
References
Publications (0)
Data not yet available
No reference posted for this study.